CriticalCentrally-acting antiadrenergic agent×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
The antihypertensive effect of methyldopa is probably due to its conversion to alpha-methylnoradrenaline, which stimulates central inhibitory alpha-adrenergic receptors. Methyldopa also reduces tissue concentrations of serotonin, dopamine, noradrenaline and adrenaline (methyldopa summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) A and B and stops the enzyme from breaking down serotonin, noradrenaline and dopamine (tranylcypromine SmPC, AEMPS). According to the methyldopa SmPC, MAO inhibitors may weaken the antihypertensive effect of methyldopa (methyldopa SmPC, AEMPS). The tranylcypromine SmPC, in turn, states that tranylcypromine may increase the blood-pressure-lowering effect of methyldopa and, in isolated cases, trigger a rise in blood pressure with agitation (tranylcypromine SmPC, AEMPS). The US tranylcypromine label names a hypertensive reaction as the main risk of the combination with methyldopa (tranylcypromine label, US Food and Drug Administration, FDA). Full MAO activity returns 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine FDA label).
Symptoms
According to the US tranylcypromine label, the main risk of the combination is a hypertensive reaction (tranylcypromine label, US Food and Drug Administration, FDA). The Spanish tranylcypromine summary of product characteristics (SmPC) describes both outcomes: the blood-pressure-lowering effect of methyldopa may increase, or, in isolated cases, blood pressure rises instead, with agitation (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). A hypertensive crisis with tranylcypromine may come with a fast heart rate, facial flushing, headache (especially at the back of the head), neck stiffness, nausea, vomiting and sensitivity to light. In isolated cases, particularly with a drug interaction, it may lead to intracranial haemorrhage (tranylcypromine SmPC, AEMPS). In a hypertensive emergency, blood pressure is severely raised (for example, above 180/120 mm Hg), there are signs of organ damage, and sweating, dilated pupils, shortness of breath, confusion, constricting chest pain and seizures may occur (tranylcypromine FDA label). Low blood pressure, including on standing, is very common with tranylcypromine itself (tranylcypromine SmPC, AEMPS). The methyldopa SmPC also lists orthostatic hypotension among its adverse reactions (methyldopa SmPC, AEMPS). At tranylcypromine doses above 30 mg a day, orthostatic hypotension may cause fainting (tranylcypromine FDA label).
Management
The combination is contraindicated. The Spanish methyldopa summary of product characteristics (SmPC) prohibits methyldopa during treatment with monoamine oxidase inhibitors (MAOIs), and tranylcypromine is an irreversible, non-selective MAOI according to its own SmPC (methyldopa and tranylcypromine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US methyldopa label also contraindicates methyldopa in patients on MAOI therapy, and the US tranylcypromine label lists methyldopa by name among contraindicated drugs (methyldopa and tranylcypromine labels, US Food and Drug Administration, FDA). The Spanish tranylcypromine SmPC is less strict: it does not prohibit methyldopa and only states that tranylcypromine may increase the blood-pressure-lowering effect of methyldopa or, in isolated cases, raise blood pressure (tranylcypromine SmPC, AEMPS). The Spanish methyldopa SmPC also contraindicates methyldopa in depression (methyldopa SmPC, AEMPS), and tranylcypromine is used for major depressive disorder (tranylcypromine SmPC, AEMPS). Start tranylcypromine no earlier than 4–5 half-lives of methyldopa and its active metabolites after stopping methyldopa (tranylcypromine FDA label). The methyldopa documents give no interval after stopping tranylcypromine, but MAO inhibition may persist for up to 10 days. Take this into account before giving drugs that interact with tranylcypromine (tranylcypromine FDA label). Measure blood pressure before starting tranylcypromine and monitor it closely during treatment (tranylcypromine FDA label). If the drugs have nevertheless been taken together and palpitations, headache or other early signs of a hypertensive crisis appear, interrupt treatment and assess the patient at once. Immediately stop tranylcypromine and any other drug that may have caused the crisis. If blood pressure is above 180/120 mm Hg with signs of organ damage, lower it immediately (tranylcypromine FDA label). The Spanish tranylcypromine SmPC recommends treating a dangerous fall in blood pressure preferably with a continuous noradrenaline infusion and careful blood pressure monitoring (tranylcypromine SmPC, AEMPS, overdose section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1
- AEMPS: Ficha técnica: Metildopa, Aldomet Forte 500 mg (nº registro 53587), sección 4.3 (2024)– AEMPS, CIMA, nº registro 53587 (Aldomet Forte 500 mg comprimidos recubiertos con película, H.A.C. Pharma; ficha común con Aldomet 250 mg), revisión 02/2024 (texto revisado 06/2018), secciones 4.3, 4.5, 4.8 y 5.1
- FDA: Methyldopa tablets (Rising Pharma) prescribing information (2025)– FDA, DailyMed setid 9e22e1d8-04ec-4b67-92ea-b09c706f2703 (Rising Pharma Holdings), versión 3, revisión 03/2025, Contraindications, Clinical Pharmacology y Precautions